Meditrina Pharmaceuticals, Inc has completed a contract manufacturing agreement for drug product development and active pharmaceutical ingredient (API) supply with a unit of Pfizer CentreSource (PCS), a leading supplier of APIs and dosage form manufacturing, for the company's lead product candidate, Femathina (MPI-674).

Currently in phase II clinical trials, MPI-674 is an aromatase inhibitor that Meditrina is repurposing for the treatment of several serious women's health conditions including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB).

"We are delighted to have such a skilled and reputable manufacturing partner for MPI-674," said Holly Vene, COO and vice president, business development, Meditrina Pharmaceuticals, Inc. "Securing a high-quality commercial supply chain partner has been a key focus of the organization and represents an important milestone in advancing our product development programme".

"We look forward to working with Meditrina, a respected and innovative company that is also located in Michigan, a state in which PCS has deep roots," commented Michael J Kosko, president, Pfizer CentreSource. "And we are delighted to be able to contribute our development and manufacturing expertise to the supply of this product".

MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.

AIs are currently used for the chronic treatment of estrogen-dependent tumours in postmenopausal women and are being investigated in a variety of women's health conditions. Meditrina holds the exclusive worldwide rights to patent applications covering the use of AIs in gynaecologic indications, including for endometrial thinning prior to hysteroscopic procedures.

Meditrina Pharmaceuticals, Inc. is a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, with an initial focus on gynaecologic and aromatase-mediated conditions with serious unmet medical needs.